| Company Name: |
NCE Biomedical Co.,Ltd. |
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
- CAY10505
-
- $155.00
-
2026-07-27
- CAS:1218777-13-9
- Purity: 99.79%
- Supply Ability: 10g
|
| | CAY10505 Basic information |
| Product Name: | CAY10505 | | Synonyms: | CAY10505;(5E)-5-[[5-(4-Fluorophenyl)-2-furanyl]methylene]-2,4-thiazolidinedione;(E)-5-((5-(4-fluorophenyl)furan-2-yl)methylene)thiazolidine-2,4-dione;CAY10505 ( 5E)-5-[[5-(4-Fluorophenyl)-2-furanyl]methylene]-2,4-thiazolidinedione;CAY10505, >=98%;2,4-Thiazolidinedione, 5-[[5-(4-fluorophenyl)-2-furanyl]methylene]-, (5E)-;CAY10505 USP/EP/BP;CAY10505 CAY-10505 | | CAS: | 1218777-13-9 | | MF: | C14H8FNO3S | | MW: | 289.28 | | EINECS: | | | Product Categories: | Akt;mTOR;PI3K;PI3K/Akt/mTOR;Inhibitors | | Mol File: | 1218777-13-9.mol |  |
| | CAY10505 Chemical Properties |
| density | 1.466 | | storage temp. | Store at -20°C | | solubility | insoluble in EtOH; insoluble in H2O; ≥14.45 mg/mL in DMSO | | form | solid | | pka | 7.21±0.20(Predicted) | | color | Light yellow to yellow |
| | CAY10505 Usage And Synthesis |
| Uses | CAY10505 is a phosphoinositide 3-kinase gamma (PI3Kγ) specific inhibitor and improves hypertension-associated vascular endothelial dysfunction. | | Biological Activity | cay10505 is a potent and selective pi3kγ inhibitor (ic50= 30 nm)pi3k (phosphatidylinositol-4,5-bisphosphate 3-kinase) is a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. it plays a key role in pi3k/akt/mtor pathway.in neurons treated with 3.5 μm ba, 200 nm cay10505 partially reduced the baicalein-induced akt phosphorylation. [1]in hypertensive rats, cay10505 at 0.6 mg.kg-1 p.o. exhibited the following effects 1) effectively reduced mabp; 2) significantly ameliorated vascular endothelium dysfunction in hypertensive rats in combination of doca; 3) prominently increased serum nitrite and/or nitrate concentrations.4) prevented hypertension-induced attenuation of ach-induced endothelium-dependent relaxation.[2] | | in vivo | Administration of CAY10505 (0.6 mg/kg, p.o.), Losartan (25 mg/kg, p.o.), or Atorvastatin (30 mg/kg, p.o.) significantly increases serum nitrite and (or) nitrate concentrations in hypertensive rats. Acetylcholine (ACh) and Sodium nitroprusside (SNP) produce endothelium-dependent and-independent relaxation in isolated rat aortic ring precontracted with Phenylephrine (3 μM), in a dose dependent manner. Administration of CAY10505 (0.6 mg/kg,p.o.), Losartan (25 mg/kg, p.o.), or Atorvastatin (30 mg/kg, p.o.) significantly prevents hypertension-induced attenuation of ACh-induced endothelium-dependent relaxation. Deoxycorticosterone acetate salt (DOCA, 40 mg/kg, s.c.) induced hypertension markedly attenuates acetylcholine-induced endothelium-dependent relaxation, but does not affect SNP-induced endotheliumindependent relaxation[3]. | | IC 50 | PI3Kγ: 30 nM (IC50, Neurons) | | references | [1] tyagi s, sharma s, budhiraja rd. effect of phosphatidylinositol 3-kinase-γ inhibitor cay10505 in hypertension, and its associated vascular endothelium dysfunction in rats. can j physiol pharmacol. 2012 jul;90(7):881-5.
[2] sun yy, lin sh, lin hc et al. cell type-specific dependency on the pi3k/akt signaling pathway for the endogenous epo and vegf induction by baicalein in neurons versus astrocytes. plos one. 2013 jul 19;8(7):e69019. |
| | CAY10505 Preparation Products And Raw materials |
|